Inflammation, Apoptosis, and BPH: What is the Evidence?

Novara, Giacomo; Galfano, Antonio; R, Berto; Ficarra, Vincenzo; Navarrete, Remigio Vela; Artibani, Walter

doi:10.1016/j.eursup.2006.02.003

Cited by 26 publications

(16 citation statements)

References 56 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…These factors stimulate proliferation and minimize cell apoptosis (15). The role of inflammation in prostate diseases is suggested by the presence of inflammatory cells within the prostate in both prostatic diseases (16). Di Silverio et al demonstrated a correlation of higher inflammatory infiltrates present in bigger prostate volume and more prone to progression of symptoms, risk of acute urinary retention and risk for surgery (17).…”

Section: Discussionmentioning

confidence: 99%

The Effect of Combined Therapy with Tamsulosin Hydrochloride and Meloxicam in Patients with Benign Prostatic Hyperplasia Symptoms and Impact on Nocturia and Sleep Quality

et al. 2013

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

The Effect of Combined Therapy with Tamsulosin Hydrochloride and Meloxicam in Patients with Benign Prostatic Hyperplasia Symptoms and Impact on Nocturia and Sleep Quality

et al. 2013

View full text Add to dashboard Cite

“…The role of inflammation in BPH is suggested by the infiltration of B lymphocytes, T lymphocytes, and macrophage to the stromal nodules of BPH [12] . However, the inflammation could be a consequence of immunity against cancer rather than a cause.…”

Section: Discussionmentioning

confidence: 99%

Histologic Influence of Doxazosin and Finasteride in Benign Prostatic Hyperplasia Accompanying Chronic Inflammation

Park¹,

Shim²

2008

Urol Int

View full text Add to dashboard Cite

Aim: To evaluate the influence of doxazosin and finasteride on histologic findings in benign prostatic hyperplasia accompanied by prostatitis, and to examine the factors related with prostate carcinogenesis. Materials and Methods: Prostate tissue from 17 cases of prostatic hyperplasia were divided into three groups; group 1: no medication history, group 2: both doxazosin and finasteride for at least 6 months before surgery; group 3: doxazosin for a minimum of 6 months before transurethral resection. Formalin-fixed, paraffin-embedded sections were stained with hematoxylin and eosin stain and immunohistochemistry for COX-2, CD3, CD68, VEGF, and GSTP (glutathione S-transferase pi). Results: CD3 showed a tendency toward decreased staining intensity and extent in group 3 (p = 0.026, p = 0.004, respectively). CD68 showed a different staining extent among the three groups (p = 0.020). For VEGF, the staining extent showed different results between groups 2 and 3 (p = 0.044). There was no correlation between COX-2 and VEGF in group 1. However, a positive correlation between COX-2 and GSTP1 was demonstrated in group 2 (p = 0.000). Conclusions: Doxazosin-treated prostate tissue showed decreased inflammatory reaction. GSTP1 expression was decreased in combined treatment with doxazosin and finasteride. These findings suggest that finasteride may interfere with the anti-inflammatory reaction. Finasteride also decreases angiogenesis. However, the meaning of our observations is limited by small sample size.

show abstract

“…A lack of this balancing has been implicated in the development of BPH (Kyprianou, 2003; Giacomo et al, 2006). …”

Section: Etiology Of Bphmentioning

confidence: 99%

“…Investigation into the mechanisms of action of the drugs that are currently being used in BPH management suggested possible interactions with apoptotic mechanisms (Giacomo et al, 2006). For example, previous studies on rat prostates showed that finasteride induced apoptosis in epithelial cells, inhibiting insulin-like growth factors (IGF) I and 1R expressions (Huynh et al, 1998).…”

Section: Etiology Of Bphmentioning

confidence: 99%

Management of Benign Prostatic Hyperplasia: Could Dietary Polyphenols Be an Alternative to Existing Therapies?

Eleazu¹,

Eleazu

Kalu

2017

Front. Pharmacol.

View full text Add to dashboard Cite

The incidence of benign prostatic hyperplasia (BPH) is gradually on the increase. While conventional drugs such as the α1-adrenergic receptor antagonists and 5α-reductase inhibitors have been found to be useful in the treatment of BPH, the adverse side effects associated with their usage, have led to increased search for alternative means of managing this disease. Furthermore, although surgery has also been suggested to be a sure method, the cost and risks associated with it excludes it as a routine treatment. Dietary polyphenols have gained public interest in recent times due to their roles in the prevention of various diseases that implicate free radicals/reactive oxygen species. However, their roles in the management of BPH have not been explored. Hence, this review on their prospects in the management of BPH and their mechanisms of action. Literature search was carried out in several electronic data bases such as PubMed, Google Scholar, Medline, Agora, and Hinari from1970 to 2017 to identify the current status of knowledge on this concept. The findings from these data bases suggest that while dietary polyphenols may not replace the need for the existing therapies in the management of BPH, they hold promise in BPH management which could be explored by researchers working in this field.

show abstract

Inflammation, Apoptosis, and BPH: What is the Evidence?

Cited by 26 publications

References 56 publications

The Effect of Combined Therapy with Tamsulosin Hydrochloride and Meloxicam in Patients with Benign Prostatic Hyperplasia Symptoms and Impact on Nocturia and Sleep Quality

The Effect of Combined Therapy with Tamsulosin Hydrochloride and Meloxicam in Patients with Benign Prostatic Hyperplasia Symptoms and Impact on Nocturia and Sleep Quality

Histologic Influence of Doxazosin and Finasteride in Benign Prostatic Hyperplasia Accompanying Chronic Inflammation

Management of Benign Prostatic Hyperplasia: Could Dietary Polyphenols Be an Alternative to Existing Therapies?

Contact Info

Product

Resources

About